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Abstract 
Background&Aims: Thyroid disorders are frequently associated 
with diabetes in clinical practice. The purpose of this study is to assess 
prevalence of associations between Graves - Basedow disease and diabetes 
or other changes in glycemic balance in an adults group. Methods: The 
studied group was of 650 people with diabetes and other changes in glycemic 
balance aged between 18 and 79 years. The methods of investigation were 
represented by clinical, imaging, biochemical, hormonal and immunological 
parameters. Results: The prevalence of Graves – Basedow disease in the 
study group was 22.61% (21.76% F vs. 30.64% M, p = 0.11, X2 = 2.53). 
Graves – Basedow disease prevalence for type 1diabetes was 10% (9.09% F 
and 20% M, p = 0.38, X2 = 0.75), 20.68% for type 2 diabetes (21.03% F and 
18.42% M, p = 0.71, X2 = 0.14), 23.49% for impaired glucose tolerance 
(IGT) (23.12% F and 30% M, p = 0.61, X2 = 0.25), and 32.47% for impaired 
fasting glucose tolerance (IFG) (27.77% F and 88.88% M p = 0.00016, X2 = 
14.15). Significant differences in this prevalence were found only between 
type 1 diabetes and other changes in glycemic balance (10% vs. 23.49%, p = 
0.023, X2 = 5.11 for IGT, 10% vs. 32.47%, p = 0.001, X2 = 10.73 for IFG). 
Conclusions: Graves – Basedow disease was mainly associated with IGT 
and IFG that occurred due to the presence of excess thyroid hormone. We 
don’t find significant differences in the gender (except IFG - predominantly 
in males).  
 
Keywords: Graves - Basedow disease, diabetes, other changes in glycemic 
balance, adults  
 
 
 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
2 
Introduction 
Thyroid disorders are frequently associated with diabetes in clinical 
practice. In the case of diabetes mellitus (DM) type 1, because autoimmune 
etiology it is often associated with autoimmune thyroid disease (chronic 
autoimmune thyroiditis, Basedow-Graves disease). In the case of DM type 2 
and other changes in glycemic balance, they usually appear secondary to 
excess of thyroid hormone or association is random. 
Graves’ disease is a type of autoimmune problem that causes the 
thyroid gland to produce too much thyroid hormone, which is called 
hyperthyroidism. Graves’ disease is often the underlying cause of 
hyperthyroidism. 
Autoimmune problems—of which there are many different types—
develop when your immune system causes disease by attacking healthy 
tissues. Researchers do not completely understand what causes 
autoimmunity, although there seems to be a genetic connection, as cases of 
Graves’ disease tend to run in families. For unknown reasons, like many 
autoimmune diseases, Graves’ is also more likely to affect women than men. 
The world incidence of the Graves-Basedow disease and the toxic 
multinodular goiter varies depending on the iodine intake. Compared to 
world regions with low iodine intake in the United States are more cases of 
Graves-Basedow disease and fewer cases of multinodular goiter (Yeung et 
al, 2005).  
Graves-Basedow disease is the most common form of 
hyperthyroidism. Approximately 60-80% of cases of this disease are 
provided thyrotoxicosis. The annual incidence of the disease is 0.5 cases per 
1,000 people, with a peak between 20-40 years. Multinodular toxic goiter 
(15-20% of thyrotoxicosis) occurs more frequently in areas deficient in 
iodine. Most people in the U.S. have sufficient iodine intake, the incidence of 
multinodular toxic goiter was lower than in iodine deficient regions of the 
world. Toxic adenoma is the cause of 3-5% of thyrotoxicosis (Lee et al, 
2006). 
Thyroid disorders have a peak incidence in the population aged 20-40 
years. Toxic multinodular goiter occurs in subjects who have a long history 
of non-toxic goiter and, therefore, are usually present at the age of 50 years. 
Patients with toxic adenomas have this condition at a younger age than those 
with toxic multinodular goiter (Lee et al, 2006).  
All thyroid diseases occur more frequently in women than in men. 
For example, in the case of autoimmune Graves - Basedow disease, the ratio 
M/F = 1/5-10. Toxic multinodular goiter and toxic adenomas occur more 
frequently in women than in men, with a ratio of 1/2-4 (Lee et al, 2006). 
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By contrast, hyperthyroidism is less common, with a female/male 
ratio of 9/1. Graves' disease is the most common and usually affects young 
adults. Toxic multinodular goiter usually occurs in older people (Wu, 2000).  
Patients with diabetes have a high prevalence of thyroid disease 
compared with non-diabetic population (Wu, 2000).   
Because patients with organ-specific autoimmune disease are at risk 
of developing other autoimmune diseases and thyroid disorders are more 
common in women, it is not surprising that 30% of women with type 1 
diabetes presents thyroid damage. Postpartum thyroiditis rate in diabetic 
patients is three times higher than in healthy women (Wu, 2000).  
A number of studies also indicate an increased prevalence of thyroid 
disease in patients with type 2 diabetes, hypothyroidism being the most 
common disorder encountered (Cooper et al, 2003). Thyroid disorders in the 
general population have a prevalence of 6.6%. In patients with diabetes, 
thyroid disease prevalence is between 10.8% and 13.4%, consisting of: 
clinical hypothyroidism (36%) sub clinical hypothyroidism (41%), 
hyperthyroidism (12%), and postpartum thyroiditis (11%) (Wu, 2000). 
DM is associated with endocrine and systemic disease with 
autoimmune etiology of type: Graves-Basedow disease, Hashimoto's 
thyroiditis, Addison's disease, celiac disease, pernicious anemia, myasthenia 
gravis, vitiligo, etc. (Cooper et al, 2003).  
From people with DM type 1, ≈ 1-100 patients develop Graves' 
disease (De Block, 2000) and ≈ 1-20 patients are generally affected by 
hypothyroidism (De Block, 2000). The frequency of DM type 1 association 
with hyperthyroidism and hypothyroidism varies from 3.2% to 4.6% and 
from 0.7% to 4% (Radaideh et al, 2003)).  
In the case of association between impaired glucose tolerance (IGT) 
and impaired fasting glucose tolerance (IFG) with thyroid disorder, they 
usually occur as a result of excess thyroid hormone. It was found that these 
associations are more common in women. 
In a U.S. study it is shows that in patients with thyroid disorders, 
glucose intolerance was present in 38% of cases, and the incidence of 
clinical diabetes was ≈ 2-3% (Wartofski, 2000, Werner et al, 2000).  
Type 2 diabetes is often associated with hyperthyroidism (Graves-
Basedow disease and toxic multinodular goiter). Type 2 diabetes is present in 
11% of patients with Graves-Basedow disease and in 5% of those with toxic 
multinodular goiter. Glucose intolerance is also frequently associated with 
hyperthyroidism, its prevalence is much higher compared to DM type 2 
(72.3%). In the case of toxic multinodular goiter, incidence of glucose 
intolerance was significantly increased (85%), respectively 54% in the case 
of Graves-Basedow disease (Paul et al, 2004). 
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I: 
MATERIAL AND METHODS 
Investigated population  
650 people with diabetes and other changes in glycemic balance (588 
F and 62 M) aged between 18 and 79 years represented the study group.  
Depending on glycemic balance the group was divided into: 
- The group with DM type 1 – 60 
- The group with DM type 2 – 290 
- The group with IGT – 183 
- The group with IFG – 117 
Figure 1. Cases distribution according to the type of changes in glycemic balance 
 
METHODS OF INVESTIGATION  
The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated hemoglobin, 
investigation of the thyroid gland: TSH, FT4, FT3, thyroid antibodies. 
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the OGTT at 2 h between 140 
- 200 mg% and impaired fasting glucose - values between 110 - 125 mg% 
and OGTT at 2 h under 140 mg%.  
Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
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To determine the TSH level in plasma, the free fraction of 
triiodotironin (FT3), and the plasma free fraction of thyroxin (FT4) were 
performed a quantitative method ARCHITECT; witch is an immunological 
method, Chemilumnescent Micro particle Immunoassay (CMIA). Normal 
values were following: TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, 
FT4 = 10-28.2 pmol/l. 
The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antiTPO and antiTg antibodies).  
To determine serum levels of antiTPO antibodies it was used the kit 
AxSYM antiTPO, an immunological method (Micro particle Enzyme 
Immunoassay) (MEIA). Normal values:  antiTPO antibodies <35 IU/ml.  
To determine serum levels of antiTg antibodies it was used the kit 
AxSYM antiTg, a MEIA method as well (Micro particle Enzyme 
Immunoassay). Normal values: antiTg antibodies <55 IU/ml.  
Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
An increased density, uniform, characterizes normal thyroid parenchyma 
easily distinguished from the neck muscles that are hypo dens.  
Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
Chronic autoimmune thyroid disorder appears with a hypoecogenity 
of the parenchyma and normal or increased thyroid volume.  
 
STATISTICAL ANALYSIS 
For statistical analysis we used Microsoft Excel and POP Tools from 
Microsoft Office 2003 and EPI 2000 program. To measure the quantitative 
variables were determined average and standard deviation, and to assess the 
gender differences and other differences we used the unpaired t test and 
ANOVA test, considering statistically significant a p < 0.05. 
 
RESULTS AND DISCUSSION 
Adults group included 650 people, young adults, adults and the 
elderly, aged between 17 and 79 years (Table I). It consisted of subjects with 
diabetes which in time present thyroid diseases and subjects with thyroid 
disease who have developed glucose metabolism disorders or diabetes.  
 
 
 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
6 
Table I. Distribution according to age and gender of adults group 
Age Cases number Female Male 
n % n % n % 
18 – 19 years 11 1.7 10 90.9 1 9.1 
20 – 29 years 29 4.46 27 93.1 2 6.9 
30 – 39 years 48 7.38 43 89.58 5 10.42 
40 – 49 years 168 25.84 141 83.93 27 16.07 
50 – 59 years 219 33.7 209 95.43 10 4.57 
60 – 69 years 118 18.15 112 94.91 6 5.09 
70 – 79 years 57 8.77 46 80.7 11 19.3 
 
Adults group was subdivided according to the type of change in 
glycemic balance in four subgroups (Fig. 1):  
- group with DM type 1 with 60 cases (9.23%)  
- group with DM type 2 with 290 cases (44.61%)  
- IGT group with 183 cases (28.15%)  
- IFG group with 117 cases (18%) 
The data obtained show that on the first place is type 2 diabetes 
(44.61%), followed by other types of changes in glycemic balance IGT 
(28.15%) and IFG (18%). DM type 1 met in the lowest proportion (9.23%). 
In the world, predominant is type 2 diabetes with a prevalence of 4.6%, 
while the prevalence of type 1 diabetes is 0.1%.  
In Romania, 7% of diabetic patients presenting DM type 1, the 
remaining 93% were patients with type 2 diabetes. 
Regarding the gender distribution, 588 people in the study were 
female (90.46%) and 62 males (9.54%), with a ratio F/M = 9.48/1 (Fig. 2). 
Patient selection corresponds with the literature, knowing that the incidence 
of thyroid disease is more common in women. In the case of DM type 1 
group, gender distribution was net in favor of women being represented by 
55 women (91.66%) and 5 men (8.34%), in ratio F/M = 11/1.  
 Around the world, a number of studies show a predominance of 
males in the incidence of type 1 diabetes in young adults. This male’s 
predominance has been observed especially after puberty (Karvoven et al, 
2003). 
In the study group, we had a predominance of females, because of the 
association of DM with thyroid disorder, diseases that prevail in women.  
In the case of DM type 2 group, gender distribution was net in favor 
of women being represented by 252 women (86.9%) and 38 men (13.1%), in 
ratio F/M = 6.6 /1. Around the world, women predominate in some areas, 
while in other men.  
In the DECODE study, the prevalence of type 2 diabetes was higher 
in women, while in the AusDiab study was higher in males (Tong et al, 
2003). 
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In the case of IGT group, gender distribution was net in favor of 
women being represented by 173 women (94.5%) and 10 men (5.5%), in 
ratio F/M = 17.3/1.  
Figure 2. Distribution by gender of adults cases with changes in glycemic balance 
 
In the case of IFG group, gender distribution was net in favor of 
women being represented by 108 women (92.3%) and 9 men (7.7%), in ratio 
F/M = 12/1.  
In the DECODE study, IFG was more frequent in men than in 
women, whereas IGT was more frequent in women than in men (The 
DECODE study group, 2003). 
In the DECODA study, IFG prevalence was higher in men than 
women in China and Japan, while in the Indians prevailed in women 
compared to men. IGT was more frequent in women than in men in Chinese 
and Japanese, this difference unnoticed in the Indians (The DECODA study 
group, 2003). In the study group, both IGT and IFG were more common in 
women, aspect consistent with increased prevalence of thyroid disease in 
women.  
The mean age of the study group was 52 ± 12.46 years, median 52 
years, with a minimum of 17 years and a maximum of 79 years.  
The group of adults with type 1 diabetes included 60 people, young 
adults, adults and elderly, aged 18-72 years. 
The current average age and the onset average age of DM in the 
adult’s subgroups with different changes in glucose metabolism is shown in 
Table II.  
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Table II. Distribution of adult’s subgroups with different changes in glucose metabolism by 
current age and by onset age 
Para 
meters 
Cases 
num 
ber 
Average Standard 
deviation 
Median Minimum Maximum 
DM type 1 
Onset age 
(years) 
60 30.46 22.94 24.5 0 63 
Current 
age (years) 
60 46.08 18.95 43 18 72 
DM type 2 
Onset age 
(years) 
290 51.86 10.3 51 20 79 
Current  
age (years) 
290 55.43 10.73 54 20 79 
IGT 
Onset age 
(years) 
183 48.84 10.61 50 17 76 
Current  
age (years) 
183 49.32 10.64 51 17 76 
IFG 
Onset age 
(years) 
117 50.7 12.76 52 20 73 
Current 
age (years) 
117 50.88 12.69 52 20 73 
 
The onset average age of type 1 diabetes corresponds with the 
literature, because it is known that type 1 diabetes usually occurs before 30 
years. Sometimes it may appear after 30 years, being labeled initially as type 
2 diabetes later prove to be a LADA type.  
NHANES study estimated that the prevalence of type 1 diabetes 
diagnosed between 30-74 years in the U.S. population is about 0.3% (0.1% 
from 0.6% between 30-49 years and 65-74 years) (Karvoven et al, 2003).  
The group of adults with type 2 diabetes included 290 people, young 
adults, adults and the elderly, ages 20 -79 years. 
The onset age of type 2 diabetes corresponds with the literature, 
because it is known that type 2 diabetes usually occurs after 40 years. 
DECODE study showed that in Europe type 2 diabetes met frequently 
between 40-59 years, incidence was higher in women and in the white 
population (The DECODE study group, 2003). AusDiab study showed that 
the prevalence of type 2 diabetes increases with age, from 2.7% in men and 
2.2% in women between 35-44 years to 23.5% and 22.7% at 75 years and 
over (Dunstan et al, 2002). Also, in the Mexican population, the prevalence 
of type 2 diabetes increases from 4.2% and 3.2% for men and for women 
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between 35-39 years at 23.1% for men and at 41.7% for women between 60-
64 years (Qiao et al, 2004). 
Adults group with IGT involving 183 people, young adults, adults 
and elderly, aged 17-76 years.  
Adults group with IFG included 117 people, young adults, adults and 
the elderly, ages 20 -73 years.  
The prevalence of IGT and IFG in Europe and Asia was assessed by 
2 studies: DECODE and DECODA. In Europe, the prevalence of IGT was 
less than 15% between 30-59 years and 30% over 60 years. IGT incidence 
increases linearly with age, while IFG not (Qiao et al, 2004). 
The prevalence of Graves - Basedow disease in the study group was 
22.61% (21.76% F vs. 30.64% M, p = 0.11, X2 = 2.53).  
Graves - Basedow disease prevalence in the group with type 1 
diabetes was 10% (9.09% F and 20% M, p = 0.38, X2 = 0.75), 20.68% for 
type 2 diabetes (21.03% F and 18.42% M, p = 0.71, X2 = 0.14), 23.49% for 
IGT (23.12% F and 30% M, p = 0.61 , X2 = 0.25), and 32.47% for IFG 
(27.77% F and 88.88% M p = 0.00016, X2 = 14.15).  
Graves-Basedow disease is the most common cause of 
hyperthyroidism. A study in Minnesota estimated its incidence at 30 cases 
per 100,000 people per year (Yeung et al, 2005). Graves-Basedow disease is 
responsible for approximately 60-90% of cases of thyrotoxicosis in different 
regions of the world ((Yeung et al, 2005). In the UK Wickham study, the 
incidence is reported at 100-200 cases /100.000 persons / year (Yeung et al, 
2005).  
A number of studies show associations between thyroid disease with 
diabetes and other changes in glycemic balance. The most common thyroid 
disorders are autoimmune in the case of type 1 diabetes and accompanied by 
thyrotoxicosis for type 2 diabetes and other changes in glycemic balance. 
A study in the Czech Republic shows that the prevalence of thyroid 
disease in patients with diabetes is 2-3 times higher than in non-diabetic 
patients (Vondra et al, 2005). It increases with age and is strongly influenced 
by female sex and autoimmune diabetes (Vondra et al, 2005). Type 1 
diabetes is commonly associated with endocrine and systemic disease with 
autoimmune etiology of type Graves-Basedow disease, autoimmune 
thyroiditis, Addison's disease, celiac disease, pernicious anemia, myasthenia 
gravis, vitiligo, etc. For people with type 1 diabetes ≈ 1/100 patients will 
develop Graves-Basedow disease while ≈ 1/20 patients are affected by 
autoimmune hypothyroidism. 
Prina et al. (1994) found an increased prevalence of autoimmune 
thyroid disease association with type 1 diabetes (23.4%) than expected in the 
normal population (3-5%) and shows that younger age of diabetes onset 
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appears to be significantly associated with the development of thyroid 
disease (Prina et al, 2004).  
The associations of different forms of change in glycemic balance 
with thyroid disease usually occur as a result of excess thyroid hormone. It 
was also found that these associations are more common in women.  
Maxon et al. (1975) found the association of glucose intolerance and 
thyrotoxicosis. Glucose intolerance was detected in 32% cases, 43% of 
patients having a suggestive history of diabetes (Maxon et al, 1975). 
Another study in India showed that autoimmune thyroid disease was 
diagnosed in 1.68 % of people with diabetes. DM was diagnosed in 2.3% of 
people with hypothyroidism and in 4.35 % of those with thyrotoxicosis 
(Sridhar et al, 2002). 
Perros et al. (1995) showed in a study on 1310 adult patients with 
DM that the prevalence of thyroid disease was 13.4 %, higher in women with 
type 1 diabetes (31.4 %) and lower in men with type 2 diabetes (6.9 %). 
Newly diagnosed thyroid disease was present in 6.8 % of cases, the first 
being sub clinical hypothyroidism (4.8 %), followed by overt 
hypothyroidism (0.9 %), sub clinical hyperthyroidism (0.5%) and overt 
hyperthyroidism (0.5 %). Female patients with type 1 diabetes had the 
highest risk of developing thyroid disease (12.3 %), but all patients in the 
study group had a higher incidence of thyroid disease compared to the 
general population. This study suggests that thyroid function should be 
investigated in diabetic patients annually to detect asymptomatic thyroid 
damage with increased frequency in the diabetic population (Colin et al, 
2004). 
In the case of Graves-Basedow disease, the ratio F/B was 5/1 in the 
case of the group of diabetes type 1, 7.5/1 in the case of the group with type 
2 diabetes mellitus 13.3 /1 in the case of the group with IGT and 3.75 / 1 for 
IFG. In The literature in regions where goiter is endemic, the prevalence rate 
in females can be 7/1, and in regions with endemic goiter, the ratio is lower 
(Wartofski, 2001).  
The onset average age of thyroid disease is shown in the table below: 
Table III. The onset average age of Graves – Basedow disease in the studied group 
Parameters Cases number Average Standard 
deviation 
Median 
DM type 1 6 33.33 13.57 34.5 
DM type 2 60 50.96 10.97 48 
IGT 43 45.04 10.88 49 
IFG 38 39.52 10.96 41.5 
 
The results correspond with the literature data, because Graves-
Basedow disease usually occurs in young women (20-40 years), but can 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
11 
occur at any age. Most affected are women aged 30-60 years (Wartofski, 
2001).   
Table IV. Graves – Basedow disease duration at adult studied group 
Parameters Cases 
number 
Average Standard 
deviation 
Median Minimum Maximum 
DM type 1 6 5.33 10.19 1.5 0 26 
DM type 2 60 5.76 5.68 4 0 24 
IGT 43 7.46 10.85 3 0 54 
IFG 38 5.94 11.22 1.5 0 49 
 
Table V. The interval of appearence between Graves – Basedow disease and differents 
changes in glycemic balance 
Time interval DM type 1 DM type 2 IGT IFG 
< 5 years 56.67% 67.93% 63.38% 66.66% 
5 – 10 years 30% 15.17% 18.57% 14.52% 
10 – 15 years 5% 8.27% 3.82% 5.98% 
15 – 20 years 3.33% 2.75% 4.37% 5.98% 
20 – 25 years 3.33% 3.10% 4.91% 3.42% 
25 – 30 years 1.67% 1.38% 1.64% 0% 
> 30 years - 1.38% 3.27% 3.42% 
 
Significant differences in the prevalence of Graves - Basedow disease 
were found only between type 1 diabetes and other changes in glycemic 
balance (10% vs. 23.49%, p = 0.023, X2 = 5.11 for IGT, 10% vs. 32.47%, p = 
0.001, X2 = 10.73 for IFG) and between IGT and IFG (23.49% vs. 32.47%, p 
= 0.011, X2 = 6.34).  
Regarding the occurrence of Basedow-Graves disease in relation to 
diabetes and other changes in glycemic balance, in most cases the interval 
was between 0 – 10 years.  
So, in the case of DM type 2, IGT and IFG, these appear after Graves 
– Basedow disease because of excess of thyroid hormones (in the case of 
surgery, because of replacement therapy with thyroid hormones). For DM 
type 1, this association is because of autoimmune origin.  
The glycemic imbalance was mild in the case of DM type 2, IGT and 
IFG, most being treated with diet, and in the case of DM type 1 was severe, 
causing even ketoacidosis.  
 
Conclusion 
Graves - Basedow disease was mainly associated with other changes 
in glycemic balance (IGT and IFG) that occurred due to the presence of 
excess thyroid hormone 
In 10% of cases were associated with type 1 diabetes due to 
autoimmune origin, part of the polyglandular autoimmune syndrome type III. 
We don’t obtained significant differences regarding the gender 
(except of IFG - predominantly in males) 
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Prevalence of Basedow – Graves’s disease was increased in type 2 
diabetes, IGT and IFG due to excess thyroid hormone causing mild glycemic 
imbalance (most had to be treated with diet). 
So, if we have a patient with Graves – Basedow disease is better to 
investigate also the glucose metabolism through determination of glucose 
concentration annually.  
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